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Abstract
Splenic enlargement (splenomegaly) develops in numerous disease states, although a specific pathogenic role for the
spleen has rarely been described. In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2
V617) induces
splenomegaly and an increase in hematocrit. Splenectomy is sparingly performed in patients with PV, however, due to
surgical complications. Thus, the role of the spleen in the pathogenesis of human PV remains unknown. We specifically
tested the role of the spleen in the pathogenesis of PV by performing either sham (SH) or splenectomy (SPL) surgeries in a
murine model of JAK2
V617F-driven PV. Compared to SH-operated mice, which rapidly develop high hematocrits after
JAK2
V617F transplantation, SPL mice completely fail to develop this phenotype. Disease burden (JAK2
V617) is equivalent in
the bone marrow of SH and SPL mice, however, and both groups develop fibrosis and osteosclerosis. If SPL is performed
after PV is established, hematocrit rapidly declines to normal even though myelofibrosis and osteosclerosis again develop
independently in the bone marrow. In contrast, SPL only blunts hematocrit elevation in secondary, erythropoietin-induced
polycythemia. We conclude that the spleen is required for an elevated hematocrit in murine, JAK2
V617F-driven PV, and
propose that this phenotype of PV may require a specific interaction between mutant cells and the spleen.
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Introduction
The mammalian spleen, an organ that is not required for adult
human life, has rarely been proposed to play a specific role in
human disease. That is, despite pathologic enlargement (spleno-
megaly) in numerous conditions, splenectomy rarely results in
reversal of the underlying disease process. Splenomegaly often
reflects an expansion of cellular proliferation outside of the bone
marrow compartment, and is called extramedullary hematopoiesis
(EMH). This process can occur not only in spleen, but also in liver,
kidney and lymph nodes. Whether EMH plays a required or
permissive role in myeloproliferative disorders (MPDs) is un-
known. Splenomegaly is observed in patients with the Philadelphia
chromosome positive MPD chronic myelogenous leukemia
(CML), for example, but splenectomy fails to affect disease
progression [1,2]. On the other hand, the role of the spleen in the
progression of another MPD, polycythemia vera (PV), has not
been tested due to frequent surgical complications [3–5]. The
pathologic hallmark of PV is increased red blood cell mass
(hematocrit) that is not mediated by the hormone erythropoietin
(Epo). Thus, PV can be distinguished from secondary polycythe-
mia by cell-autonomous proliferation or red blood cells.
In 2005, an activating mutation in the nonreceptor tyrosine
kinase Janus kinase 2 (JAK2
V617F) was found to be present in the
blood in more than 90% of patients with human PV [6–10].
Moreover, introduction of JAK2
V617F into hematopoietic cells
causes PV in mice, and inhibitors of Jak2 (Jak2i’s) reduce
hematocrit and spleen size [11]. We also observed that the
efficacy of Jak2i’s in such JAK2
V617F-driven PV in mice is
disproportionately associated with reduced disease burden entirely
in spleen, with minimal effect in bone marrow (data not shown).
Thus, efficacious treatment of murine PV with Jak2i’s suggests that
the spleen plays a critically important role in PV. In order to
specifically test the role of the spleen in JAK2
V617F –driven,
murine PV, therefore, we performed surgery either prior to or
following polycythemia-inducing bone marrow transplant of
JAK2
V617F cells, and characterized the resulting phenotype.
Methods
Animals
Six-week-old C57Bl/6 (B6) or Balb/c donor mice were obtained
from Taconic Farms Inc. (Germantown, NY). The mice were
maintained 5 to a cage in pathogen-free conditions. All animal
studies were conducted in accordance with protocols approved by
the Institutional Animal Care and Use Committee (IACUC).
Statistical Methods
A Student’s t-Test, assuming equal variance, was used to
compare hematology parameters between sham (SH) and
splenectomized (SPL) mice.
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The murine Jak2 cDNA was cloned into the retroviral vector
MSCV-IRESEGFPwhichwasgenerouslyprovidedbyDr.Gilliland,
as described [12]. We cultured 293T cells in Dulbecco modified
Eagle medium (DMEM) with 10% fetal bovine serum (FBS).
Transientcotransfectionof293T cellsby equalamountsofexpression
vectors and packaging plasmid (pCL-Eco, Imgenex, San Diego, CA)
and generation of retroviral supernatant were performed using
FuGENE (Roche, Nutley, NJ) according to the manufacturer’s
protocol. Viral supernatant was harvested after 48 hours and was
used to transduce bone marrow or NIH 3T3 cells to assess viral titer.
Jak2 V617F allele burden QPCR
Genomic DNA from 30 ul of mouse peripheral blood or 10 mg
of mouse tissue was purified by Qiagen tissue and blood DNA kit
(cat #: 69506); 10 ng of genomic DNA was used for 10 ul QPCR
reactions in 384-well plate format using ABI 7900HT Real-Time
PCR system. Primers: Jak2cDNAF2: CACATAGGAACTATT-
CAGAGTCTTTC; Jak2MutR3: AGAATGTTCTCCTCTCCA-
CAGTA (additional mutations were added to the primer to
prevent amplification of unmatching sequences).
Bone marrow transplantation and splenectomy surgery
of mice
Murine BM transplantation experiments were performed as
previously described (paper 1). Briefly, the viral titer was
determined by transducing 3T3 cells with supernatant (plus
polybrene, 10 mg/mL) and analyzed for the percentage of green
fluorescent protein–positive (GFP
+) cells by flow cytometry 2 days
after transduction. C57Bl/6 or Balb/c donor mice were treated for
5 days with 5-fluorouracil (150 mg/kg, intraperitoneal injection).
Bone marrow cells from donor mice were harvested by flushing
femurs and tibias and were cultured for 24 hours in transplant
medium (RPMI+10% FBS+6 ng/mL IL-3, 10 ng/mL IL-6, and
10 ng/mL stem cell factor). Cells were treated by spin infection
with retroviral supernatants (1 mL supernatant per 4610
6 cells,
plus polybrene, plus HEPES 30 mL/4 mL) and centrifuged at
2500 g for 90 minutes at 30uC 24 hours before and on the day of
transplantation. Whole BM cells (1.0610
6) were resuspended in
200 uL Hanks balanced salt solution and were injected into lateral
tail veins of lethally irradiated (265.5 Gy [550 rads]) C57Bl/6 or
(264.5 Gy [450 rads]) Balb/c recipient mice.
Mice were anesthetized with isoflurane inhalation. After anesthe-
sia, mice were surgically prepared by first shaving the incision site,
followed by preparing the incision site with either Betadine/alcohol
scrubs or chlorhexidene scrubs. A small incision was made in the left
subcostal abdominal wall.The spleen willbe exteriorized through the
incision, and a splenectomy will be performed by placing ligatures
around the splenic vasculature and removing the spleen. The incision
will be closed in two layers using surgical suture material and wound
clips. Mice were monitored for recovery from anesthesia and kept
until wakeup at 37uC. Control group underwent a sham surgery (SH)
and they were maintained in the same conditions.
Analysis of disease in mice
Peripheral blood was collected from the retro orbital cavity
using EDTA glass capillary tubes and analyzed by using the Advia
120 Hematology System (Bayer Diagnostics) according to the
manufacturer’s instructions.
Antibody staining and flow cytometry
Isolated bone marrow flushing by the femurs or spleen was
strained through a 70-mm strainer in the presence of RPMI and
10% fetal bovine serum. Cells were blocked with Fc-block (BD
Biosciences) for 15 minutes on ice, and stained with antibodies in
Stain Buffer (BD Biosciences) for 30 minutes on ice. Antibodies
used were allophycocyanin-alexa fluor 750 anti-mouse Ter-119
(eBioscience, San Diego, CA) and phycoerythrin anti-mouse
CD71 (BD Biosciences). After washing, cells were resuspended
in Stain Buffer containing Topo-3 (Invitrogen) to allow discrim-
ination of nonviable cells. Flow cytometry was performed on a
FACSLSRII cytometer (BD Biosciences, San Jose, CA). At least
10 000 events were acquired, and data were analyzed using
FlowJo software (Tree Star, Stanford University, Stanford, CA).
Results are presented as dot plots of viable cells selected on the
basis of scatter and Topo-3 staining. For erythroblast analysis as
previously described [13].
Results
A well-established mouse model that closely phenocopies
human PV was used to test the role of the spleen in PV. Briefly,
adoptive transfer of retro virally transduced bone marrow cells
containing mutant JAK2
V617F-GFP into lethally irradiated mice
leads to a disease that closely resembles human PV, including
elevated hematocrit and splenomegaly [12,14]. In order to test the
role of the spleen in V617F-driven PV, therefore, we removed the
spleen (SPL) or performed a sham operation (SH) 2 weeks prior to
a bone marrow transplant (BMT) of JAK2
V617F-containing bone
marrow cells. Two strains of mice, C57Bl6 and Balb/c, were used
in order to obtain generalizable data for mouse models that differ
slightly in disease phenotype [12]. All mice tolerated surgery and
the BMT procedure without complication. While SH operated
mice rapidly develop PV (Hct=61.363.6 in Balb/c and 7362.6%
in B6 mice), SPL operated mice fail to develop PV over the 7 week
observation period (45.861.4 and 49.861.9%, respectively; Fig. 1).
As would be expected after removing the splenic depot of red
blood cells (RBCs), RBC mass was higher in SH operated than
SPL mice, although this did not reach statistical significance
(sTab1). Reductions in other amplified hematopoietic lineages
such as white blood cells (WBCs) and platelets were also observed
in the SPL cohort, although these were clearly not normalized
(sTab1).
In order to rule out the possibility that a lack of PV is due to
BMT engraftment failure, we measured JAK2
V617F-GFP
+ cells in
bone marrow. As shown in Figure 2A, both SH and SPL mice
harbor similar, large (15–25%) populations of JAK2
V617F-GFP
+
cells. Similarly, mutant JAK2
V617F DNA in the bone marrow is
readily detectable and similar in SH versus SPL mice (Fig 2B).
Surprisingly, mutant JAK2
V617F allele burden in the blood of
splenectomized mice is more than double the burden in SH
(Fig 2C). This implies that the total burden of JAK2
V617F disease is
comparable in SH and SPL mice because the diseased spleen,
approximately 600–800 mg, primarily harbors mutant erythro-
blasts (sTab1). Lower hematocrits in SPL mice most likely reflects
underproduction of RBCs, as opposed to increased turnover, as
indicated by normal peripheral blood smears, LDH and bilirubin
levels, and no evidence of hemosiderin in macrophages (data not
shown). Finally, evidence of extramedullary hematopoiesis is
lacking in SPL mice, as indicated by normal liver weights,
equivalently low liver erythroid progenitor cells (sTab1), and no
pathologic enlargement of lymph nodes by visual inspection. Thus,
while JAK2
V617F mutation-bearing cells readily engraft into the
bone marrows of recipient mice, the lack of a spleen severely
impairs or prevents PV.
Histological analysis further confirms active JAK2
V617F-driven
disease in both SH and SPL mice (Fig 3). Typically, mice which
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V617F -driven polycythemia in mice. (A) 6 week old female C57Bl/6 mice underwent splenectomy (SPL,
&) or sham (SH, %) operations. (B) 6 week old female Balb/c mice underwent splenectomy (SPL, ¤) or sham (SH, e) operations. Followed by 2 week
recovery, irradiation and injection of Jak2
V617F -transduced bone marrow cells from congenic donors. Hematocrit was measured weekly until disease
was maximal in sham-operated mice (n=12/group, error bars indicate SD). Open symbols=sham operated; filled symbols=splenectomy. * indicates
p,0.05 compared to SH operated mice.
doi:10.1371/journal.pone.0007286.g001
Figure 2. Splenectomy does not alter Jak2
V617F disease burden in bone marrow. At the termination of the SPL-BMT study shown in Fig 1,
bone marrow cells were harvested and live, GFP+ cells were analyzed by flow cytometry (A) DNA from bone marrow aspirates (B) and blood (C) was
also prepared and PCR for Jak2
V617F allele was performed. *p,0.01 compared to SH operated mice (n=6 mice/group in all groups).
doi:10.1371/journal.pone.0007286.g002
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V617F BMT sequentially develop myeloid and
erythroid hypercellularity, increased numbers of megakaryocytes
and reticulin fibrosis. As shown in Fig 3, compared to age-
matched, normal B6 mice, megakaryocytosis and reticulin fibrosis
is readily identifiable in the bone marrow of both SH and SPL
JAK2
V617F- transplanted mice. Progressive JAK2
V617F-driven
disease in Balb/c mice, as exemplified by new bone formation
(osteosclerosis) and extensive, nonlinear reticulin fibrosis is
similarly seen in the bone marrow of both SH and SPL mice
(Fig 3, right panels). Similarly, mice which undergo SPL after
BMT still show hypercellularity and reticulin fibrosis despite
normalized hematocrit (Fig 3, lower panels). These findings
demonstrate that JAK2
V617F-driven, elevated hematocrit (polycy-
themia) can be pathologically independent of JAK2
V617F-driven
fibrosis/osteosclerosis in bone marrow. This would suggest that
splenectomy, while effective at reducing JAK2
V617F-driven
pathology in blood (elevated hematocrit), does not alter the
pathologic course of JAK2
V617F-driven PV in bone marrow.
If an intact spleen is required for establishment of PV, is it
required for maintenance of PV? In order to test this, PV
burdened mice were generated via JAK2
V617F-GFP BMT and the
spleens were removed posttransplant 4 weeks later. In order to
assure that PV was at equilibrium, mice were not operated on until
hematocrits had uniformly reached maximal, stable values
(.64%). As shown in Fig. 4, SH operation has no effect on
hematocrit in polycythemic B6 mice, which maintain high
hematocrit levels (final 67.463.2%). In contrast, SPL results in a
rapid decline in hematocrit to normal levels in B6 mice where they
are maintained (40.663.7%, p,10
210). Normalization of hemat-
ocrit was observed in 3 separate cohorts of B6 mice at similar rates
of descent (data not shown). Balb/c mice responded similarly,
although SH operated mice also demonstrated a slight lowering of
hematocrit (Fig 4, right). Similar to what is observed when SPL
precedes BMT; mutant, GFP+ cells are easily measured in the
bone marrow of splenectomized mice (sTab2). Moreover, and as
has been well described in prior reports, splenectomy has no effect
on hematocrit in normal, non polycythemic mice (data not shown).
In conclusion, an intact spleen is required for maintenance of
JAK2
V617F-driven PV. We postulate that the spleen provides
either a required niche or a required factor(s) for JAK2
V617F-
expressing hematopoietic cells to maintain the high hematocrit
that characterizes PV.
Is a spleen required for polycythemia generally? Polycythemia
can result either from a hormone-independent, JAK2
V617F-driven
primary process, or a hormone (Epo)-dependent secondary
process. It is clear from prior reports that the spleen is not
required for maintenance of hematocrit, nor for regeneration of all
hematopoietic lineages following bone marrow transplantation
Figure 3. Pathologic fibrosis and osteosclerosis are equivalent in polycythemic and splenectomized, normocythemic mice. A. In the
SPLRBMT experiment, histology was performed on tissues from mice approximately 9–10 weeks after SH or SPL. Bone marrow histology shows
increased cellularity, prominent megakaryocytes (arrowheads) and reticulin fibrosis (thin arrows in lower panels) in both SH and SPL groups of mice
compared to age-matched normal bone marrow. In Balb/c mice, extensive new bone formation (osteosclerosis, aqua arrows) and reticulin fibrosis are
found equally in both SH and SPL mice 6 weeks after transplant. B. Splenectomy after V617F-driven PV occurs results in similar hypercellularity (top H
& E staining) and reticulin fibrosis in SH and SPL operated mice.
doi:10.1371/journal.pone.0007286.g003
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does not prevent secondary, Epo-induced polycythemia [16]. This
presents a paradox, because cell autonomous, JAK2
V617F-driven
‘‘true’’ PV requires a spleen, but cell non-autonomous, or
secondary polycythemia may not. Thus, erythropoiesis driven by
JAK2
V617F results in polycythemia that requires a spleen, while
erythropoiesis driven by wild type JAK2 does not.
In order to investigate this more fully, we tested the effects of
splenectomy on Epo-induced, secondary polycythemia in 2 strains
of mice. We first optimized a dosing regimen of recombinant
human erythropoietin (Aranesp
TM) that induces polycythemia in
mice, and closely recapitulates the pathologic hallmarks of human
PV. Administration of Aranesp 3 times over 7 days (qOD), for
example, uniformly results in polycythemia (hct.65%), reticulo-
cytosis (.25% reticulocytes) and splenomegaly (.600 mg, nor-
mal=80 mg) in both B6 and Balb/c mice [17]. Thus, this Epo-
stimulated model offers many of the major anatomic hallmarks of
human PV without the JAK2
V617F mutation. We used this model
of secondary polycythemia to investigate the role of the spleen in
secondary, Epo-driven compared to cell autonomous, JAK2
V617F-
driven PV. Both B6 and Balb/c mice underwent SH or SPL
operations, were allowed to recuperate for 2 weeks, and Aranesp
was administered three times over 1 week. As shown in Fig. 5, both
B6 and Balb/c mice readily develop polycythemia (67.561.7 and
6660.8%) and splenomegaly (624646 and 607632 mg) after SH
operation. Similarly, but in contrast to what is observed in
JAK2
V617F-driven PV, SPL mice also develop polycythemia to a
level that is more than 80% of the increase seen from normal, and
90–92% of the total hematocrit seen in SH operated mice (Fig 5).
Thus, a robust polycythemic phenotype develops in splenecto-
mized mice in response to wild type (EpoREpo receptorRJak2)
signaling. Furthermore, chronic injection of Aranesp over weeks,
inducing persistent polycythemia and splenomegaly, fails to induce
fibrosis in bone marrow or spleen (data not shown). Thus, the
pathology of Epo-induced, secondary polycythemia contrasts
sharply to JAK2
V617F-driven PV, which requires an intact spleen
and leads to fibrosis/osteosclerosis in hematopoietic tissues.
Discussion
The observed differences between the role of the spleen in
primary versus secondary polycythemia could be explained if 2
independent pathologic processes lead to elevation in hematocrit
and bone marrow fibrosis, respectively. In the first, the spleen
provides either a required factor or an anatomic niche for
JAK2
V617F-expressing cells, leading to erythrocytosis and in-
Figure 4. Splenectomy normalizes hematocrit in Jak2
V617F -driven polycythemia vera. B6 (left) and Balb/c (right) mice were injected with
V617F-transduced, congenic bone marrow cells and allowed to develop polycythemia. After sham (SH, %) or splenectomy (SPL, &) operations, mice
were followed weekly and hematocrit measured by spun hematocrit. * p,0.05 compared to SH operated mice.
doi:10.1371/journal.pone.0007286.g004
Figure 5. Secondary (Epo-stimulated) polycythemia develops
in SH and SPL mice. Eight week old B6 and Balb/c mice (n=4/group)
underwent SH or SPL operations, and 2 weeks later erythropoietin was
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to induce hematocrit elevation in splenic extracts versus splenic re-
transplantation into splenectomized JAK2
V617F-harboring mice.
These mechanisms are not mutually exclusive, however, if the
spleen elaborates a critical factor (Epo) in the PV context, for
example, thus providing both ligand stimulation a pathogenic
niche. In the second process, one or multiple of the amplified
myeloid lineages (red cell, white cell, or platelet-forming) of
JAK2
V617F-expressing cells mediate fibrosis and osteosclerosis in
the bone marrow, and this process occurs independently of
elevations in hematocrit. If indeed essential thrombocythemia
(ET), PV and primary myelofibrosis (PMF) represent a continuum
of one disease that differ in JAK2
V617F gene dosage, then it will be
critically important to know the gene dosage in patients prior to
considering splenectomy [18–20]. This consideration would be
important because SPL, although effective in lowering hematocrit,
could also potentially alter disease progression the bone marrow.
An alternative possibility is that hematopoietic competition in the
bone marrow space, in the absence of a spleen, prevents erythroid
expansion specifically. That is, if JAK2
V617F –expressing erythroid,
myeloid and megakaryocytic lineages in PV compete in the marrow
space, then splenectomy could limit pathologic expansion. In
contrast, pathologic stimulation of a single lineage of cells, via Epo
for example, results in a homogeneously (erythroid) hyper cellular
bone marrow that is sufficient to maintain elevated hematocrit. This
model has been intensively tested in mice via high-dose, ligand-
stimulation (G-CSF, Epo) competition experiments. In these
experiments, co-administration of Epo and G-CSF to splenecto-
mized mice only modestly reduces late stage granulocyte and
erythrocyte lineages, respectively, and SCF prevents this mutual
inhibition [21]. Thus, even maximal myeloid-expanding ligand
stimulation has only a modest, and not preventative, effect on
erythroid expansion even in the absence of a spleen. Further studies
could test whether the arrest of erythroid expansion after SPL in PV
is a resultofcompetitionbetween multiplehematopoieticlineagesin
a restricted space. Noting that the pathogenesis of myelofibrosis and
erythrocytosis can be dissociated by removal of the spleen, one
hypothesisis that the spleen providesa niche forspecific populations
of endogenous erythroid colony-forming cells (EECs). We were not
able to grow EECs from V617F-transplanted Balb/c mice. Thus,
additional studies might help to determine whether differences in
EEC numbers or proliferation explain normal versus polycythemic
phenotypes observed in SPL versus SH operated mice, respectively.
We recognize that secondary, Epo (Aranesp)-driven erythrocy-
tosis represents a stronger phenotype than V617F-driven polycy-
themia due to the shorter time required for progression of disease
(7 versus 14–28 days, respectively). Thus, a stronger erythropoietic
drive has the potential to explain the presence (Epo) or absence
(V617F) of polycythemia following SPL in these 2 models.
Nonetheless, these 2 models achieve similar, maximal and stable
levels of hematocrit (65%). Thus, if viewed in terms of maximal
polycythemia observed, the effect of SPL has a marked, curative
consequence in the mutant model, while only blunting the
phenotype of Epo-induced polycythemia. Additional experiments,
such as administering low-dose murine Epo chronically, or
generating a mouse expressing low levels of Epo transgenically,
would further address whether SPL has a similar effect of a similar
time frame in secondary (Epo) versus mutant-driven (V617F)
polycythemia.
Two strains of mice were used in these experiments in order to
reduce the likelihood that any effects we measured were due to
strain variations. Marked strain variations, similar to what has
been reported, were observed with respect to bone marrow and
spleen myelofibrosis [12]. For example, at 6 weeks of age the
majority of Balb/c mice harbor myelofibrosis in the bone marrow,
while none of the C57Bl6 (B6) mice show this abnormality (data
not shown). This difference is observed despite using identical
titers of V617F-containing virus, and despite similar levels of
maximal hematocrit. Later, by approximately 12–14 weeks of age,
more than 50% of the B6 mice show reticulin fibrosis in the bone
marrow. In comparison to Balb/c mice, which show marked
myelofibrosis at this stage, B6 mice show a more modest
phenotype. This variable myelofibrotic phenotype resembles that
seen in prior reports [12]. These observations agree with prior
hypotheses, which suggest that unknown genetic modifiers result in
a heterogeneous phenotype both between strains [12] and even
within a single, transgenic line of mice [19].
The amount of EMH that takes place in the spleen is likely to be
different in mice (high) than humans (modest). Nonetheless, our
finding that SPL normalizes only the erythroid lineage in mice
allows at least a theoretical extension to human PV. If, for
example, the spleen is required for primary, JAK2
V617F-driven
PV, then all patients should have splenomegaly or at least EMH in
the spleen. By clinical examination and ultrasound, the vast
majority of patients with PV do indeed have evidence of
splenomegaly [22]. The JAK2
V617F mutation can indeed be
detected in the spleen as well as BM in patients with PV, and
clonality suggests an origin in bone marrow [23]. Furthermore,
noninvasive imaging with
18F-FLT PET shows evidence of EMH
in all patients with PV, although patients with end-stage splenic
fibrosis may not be expected to have this finding [24]. We are,
furthermore, not aware of any cases of PV in patients who were
asplenic prior to the onset of disease, although absence of this data
cannot constitute proof. In order to clinically test the hypothesis
that the spleen is required for PV, it will be necessary to first
understand and control the abnormal rheology of blood, as well as
the susceptibility to infections in PV patients undergoing
splenectomy. If patients with PV can be effectively treated, spleen
size is reduced, and this treatment lowers surgical risk, then the
role of the spleen in human PV could be tested directly. We
predict that, unlike other malignant conditions (CML) that are
accompanied by splenomegaly, splenectomy in patients with PV
will reduce hematocrit to normal levels. The consequences of
residual JAK2
V617F burden in the bone marrow will be important
to characterize further.
Despite the recent and remarkable discovery that the
JAK2
V617F mutation plays a critically important role in the
development of PV, much remains unknown about its pathogen-
esis. Others and we have designed specific inhibitors of JAK2 that
may be useful therapies for PV, although their benefit over current
treatment remains to be demonstrated [25]. Our data predict that
spleen size itself will offer a highly sensitive, noninvasive
measurement of disease, and that splenectomy will prevent the
hematocrit-elevating consequences of JAK2
V617F-associated dis-
ease. We propose that a cure for PV, however, will require
reducing or ablating residual JAK2
V617F burden in the bone
marrow. Interestingly, our finding that splenectomy in JAK2
V617F-
driven, PV improves erythroid neoplasia sharply contrasts sharply
to studies which suggest that splenectomy may accelerate frank
carcinogenesis [26]. Our observations are limited to the
JAK2
V617F mutation, and cannot necessarily be extrapolated to
the remaining 5% of mutations described in human PV [27].
Finally, these data show that the spleen-dependent JAK2
V617F-
driven polycythemia is pathologically independent of JAK2
V617F-
associated reticulin fibrosis and osteosclerosis in bone marrow.
The role of the spleen in human PV, as well as other, clinically
untested splenomegaly-associated diseases remains unknown.
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7286Supporting Information
Table S1 Hematopoietic and anatomic changes in mice who
first underwent surgery (splenectomy or sham) and then
secondarily received V617F-containing cells via bone marrow
transplant. Surgery was performed, and then 2 weeks after surgery
mice were transplanted with congenic bone marrow cells that were
transduced with the V617F murine gene construct. After 7 weeks,
analysis of cellularlity, V617F mutation positive (GFP+), erythroid
(Ter119+) cells, complete blood count and organ size was
performed. Vacant data in SPL columns are due to splenectomy
performed at the start of treatment.
Found at: doi:10.1371/journal.pone.0007286.s001 (0.14 MB TIF)
Table S2 Hematopoietic changes in mice who were transplant-
ed with V617F-transduced bone marrow, and secondarily
underwent splenectomy or sham operations. Mice were first
irradiated, transplanted with congenic bone marrow cells
harboring the V617F mutation, and then surgery was performed
4 weeks later (V617FBMT-Surgery). After 7 weeks, analysis of
cellularlity, V617F mutation positive (GFP+), erythroid (Ter119+)
cells, complete blood count was performed.
Found at: doi:10.1371/journal.pone.0007286.s002 (0.13 MB TIF)
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